This is a routine administrative filing with no new financial information. The real story is the complete leadership and board turnover, plus the two recent related-party acquisitions (Zorro Net and DR. Frucht) that suggest a pivot away from the original phage therapy business. Monitor the Q1 2026 10-Q for the first financial results under the new management and the impact of these acquisitions on revenue and cash burn.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 1 $0.7900entry
- T+1 · 7mo ago −5.06%α −4.72% · $0.7500
- T+5 · 6mo ago −20.63%α −22.98% · $0.6270
- T+20 · 6mo ago +31.65%α +26.38% · $1.04
- T+60 · 4mo ago −76.78%α −79.85% · $0.1834
Price Chart
How similar events traded
Executive Summary
BiomX filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, executive compensation, security ownership, related transactions, and auditor fees) that were omitted from the original filing. This is a routine administrative amendment, no financial restatements, no auditor changes, and no new financial data. The filing also includes Section 302 certifications from the new CEO and CFO, and discloses a complete board and management overhaul that occurred in Q1 2026.
Key Facts
- Amendment adds Part III items (10-14) that were previously omitted; no financial restatements or corrections.
- Entire prior management team resigned: CEO Jonathan Solomon (March 4, 2026), CFO Marina Wolfson (Feb 24, 2026), CDO Dr. Merav Bassan (Feb 24, 2026).
- New CEO Michael Oster and CFO David Rokach appointed; entire board replaced between Jan-Mar 2026.
- Prior board members (7 total) all resigned between Feb 9 and March 4, 2026; new board of 4 directors appointed.
- Director Amir Shalom resigned April 29, 2026 after only 55 days on the board.
- Company completed two related-party acquisitions in April 2026: Zorro Net Ltd. from Water IO Ltd. (1.3M shares + $1.25M note) and 60% of DR. Frucht Systems Ltd. from Mandragola Ltd. ($750K cash + $3M convertible note + 923K shares + warrants).
- Auditor remains Kesselman & Kesselman (PwC Israel); audit fees unchanged at $190K for both 2025 and 2024.
- 10,111,516 shares outstanding as of April 30, 2026; market cap ~$4M.
- CEO and CFO surrendered shares for cancellation on April 24, 2026 (10,000 and 5,000 shares respectively), now hold zero shares.
Financial Impact
No financial data in this amendment; the original 10-K financials are unchanged.
Risk Factors
- Complete management and board turnover in Q1 2026 raises governance and strategic continuity concerns.
- Director Amir Shalom's resignation after only 55 days without explanation is a red flag.
- Related-party acquisitions (Water IO, Mandragola) with interlocking director relationships create conflict-of-interest risk.
- Company has a $4M market cap with significant dilution potential from outstanding warrants and convertible notes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001213900-26-050373 |
| Document: ea028831201ex31-2.htm | 0001213900-26-050373 |
| Document: ea028831201ex31-1.htm | 0001213900-26-050373 |
| Document: 0001213900-26-050373-index-headers.html | 0001213900-26-050373 |
| Document: 0001213900-26-050373-index.html | 0001213900-26-050373 |
| Document: 0001213900-26-050373.txt | 0001213900-26-050373 |
Track record
22 reports on PHGE
8 of 12 bullish or bearish reports moved the stock their way by T+1. Best: +62.36% at T+20 after the Jun 16, 2026 report. 8 of 12 went positive at some point.
Filters
- Oct 7, 20265w ago 8-K Neutral 4/10 Entry $0.3092 to $0.2915 ▼ −5.72% −5.30% vs SPY
- Oct 7, 20265w ago DEF 14A Bearish 6/10 Entry $0.3092 to $0.2915 ▲ +5.72% +5.30% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $0.1425 to $0.1421 ▼ −0.28% −1.33% vs SPY
- Aug 28, 202611w ago 8-K Neutral 4/10 Entry $0.1371 to $0.1430 ▲ +4.30% +4.99% vs SPY
- Aug 5, 202614w ago Press Release Bearish 5/10 Entry $0.1800 to $0.1598 ▲ +11.22% +11.06% vs SPY
- Jul 28, 202615w ago 8-K Bearish 8/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 28, 202615w ago Press Release Bearish 7/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 27, 202616w ago 424B5 Bearish 7/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 8, 202618w ago Press Release Neutral 4/10 Entry $0.2758 to $0.2800 ▲ +1.52% +0.68% vs SPY
- Jul 2, 202619w ago 8-K Bearish 6/10 Entry $0.3190 to $0.3020 ▲ +5.33% +6.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers